scholarly journals Associated pathogenesis of bladder cancer and SARS-CoV-2 infection: a treatment strategy

VirusDisease ◽  
2021 ◽  
Author(s):  
Mukul Kumar Singh ◽  
Mayank Jain ◽  
Hari Shyam ◽  
Pratap Shankar ◽  
Vishwajeet Singh
Keyword(s):  
Bladder Cancer ◽  
Treatment Strategy

scholarly journals MP44-11 BIOMARKER-DRIVEN TARGETED ORAL TREATMENT STRATEGY FOR BLADDER CANCER

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Daley Schimmelpfennig ◽  
Michael W. Kemper ◽  
Soum D. Lokeshwar ◽  
Andre Jordan ◽  
Vinata B. Lokeshwar
Keyword(s):  
Bladder Cancer ◽  
Treatment Strategy ◽  
Oral Treatment

scholarly journals Comparison of the EORTC and CUETO prognostic models in non-muscle-invasive bladder cancer

2018 ◽  
Vol 14 (2) ◽  
pp. 162-170
Author(s):  
A. D. Kaprin ◽  
O. I. Apolikhin ◽  
B. Ya. Alekseev ◽  
D. A. Roshchin ◽  
A. A. Kachmazov ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Strategy ◽  
Scoring Systems ◽  
Prognostic Models ◽  
Invasive Bladder Cancer ◽  
Molecular Characteristics ◽  
Muscle Invasive Bladder Cancer ◽  
European Organization ◽  
Genetic Characteristics ◽  
Muscle Invasive

Bladder cancer is one of the most common malignant diseases involving the urinary system. Accurate prediction of the disease course and outcome is crucial for choosing an appropriate treatment strategy in these patients. Currently, there are several prognostic models for predicting non-muscle invasive bladder cancer outcomes. The scoring systems developed by the European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Urological Club for Oncological Treatment (CUETO) are the most widely used prognostic models for bladder cancer. Despite the undeniable merits of these scales, they need to be supplemented. Since the prognostic score has a direct impact on the treatment strategy, intensity and costs of postoperative follow-up, and outcome, its accuracy should be higher than it is now. Identifying the additional parameters that would increase the robustness of these models is one of the major challenges for researchers.The molecular and genetic characteristics of the tumor, that can be estimated after the first surgery, are probably the best candidates for this role. The main limitation of these prognostic models lies in the fact that they assess only morphological properties of the tumor, while the most important molecular characteristics are neglected. These scoring systems do not evaluate clinical factors, concomitant diseases, and iatrogenic complications occurring during the treatment of relapses. The assessment of molecular mechanisms and clinical characteristics underlying the development of non-muscle-invasive bladder cancer as well as identification of key molecular markers, that could complement the currently existing risk assessment models, are the most important goals for researchers dealing with bladder cancer. It will significantly improve predictive capabilities of these models, ensuring the choice of an optimal treatment strategy.

MP65-03 INHIBITION OF PEG10 MAY BE A NOVEL TREATMENT STRATEGY FOR A SUBSET OF BLADDER CANCER.

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Yoshihisa Kawai ◽  
Fan Zhang ◽  
Shusuke Akamatsu ◽  
Tetsutaro Hayashi ◽  
Kenjiro Imada ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Strategy ◽  
Novel Treatment

scholarly journals Evaluation of Second-Look Transurethral Resection in Re-Staging of Patients With Superficial Bladder Cancer

2020 ◽  
Vol 18 (1) ◽  
pp. 16-22
Author(s):  
Md Masud Zaman ◽  
Md Sajid Hasan ◽  
Golam Mowla Chowdhury ◽  
Md Shafiqur Rahman ◽  
AKM Mahbubur Rahman
Keyword(s):  
Risk Factors ◽  
Bladder Cancer ◽  
Transurethral Resection ◽  
Treatment Strategy ◽  
Superficial Bladder Cancer ◽  
Bladder Tumour ◽  
Malignant Tissue ◽  
Second Look ◽  
Muscle Invasive ◽  
Initial Resection

Objective: The Objective of this study was to evaluate the second-look transurethral resection (TUR) from the base of the previously resected bladder tumour in avoidance of staging errors, possibility of changing treatment strategy, and determination of risk factors of up-staging in patients with a diagnosis of superficial bladder cancer. Materials and Methods: In this cross sectional study, 50 cases of superficial bladder cancers (pTa and pT1) were included where muscle coat were absent in histopathologic report of first TURBT. A second-look TUR from the tumour site were done after 4 weeks following the initial resection. At the second-look TUR, resection from the base of the previously resected area was performed for restaging. Finally, histopathologic findings of the second TURBT were compared with those of the initial one by appropriate statistical analysis. Results: Out of 50 patients, 27 (54%) had residual malignant tissue in histopathological report of second-look TUR, while 23 (46%) were tumour free (no residual malignant tissue) at second-look TUR. In this study, total up-staging of tumour found in 18 (36%) patients. Out of them, 6 (12%) and 2(4%) patients were up-staged from pTa to pT1 and PT2 respectively. 10 (20%) were up-staged from PT1 to muscle-invasive (pT2). So, total percentage of staging errors (under staging) detected in second-look TUR was 36% cases. Appearance (sessile), size (>3 cm) and stage (pT1) of the tumour at the initial resection were independent risk factors for up-staging to muscle invasive disease detected at second-look TURBT. Conclusions: Second-look TURBT is a valuable procedure for detection of residual tumour and accurate staging of non-muscle invasive bladder tumour. It also changed the treatment strategy of a significant proportion of patients. It is useful for tumours at high risk of recurrence and progression such as large size, sessile, multiple and T1 high grade tumours, particularly when there is inadequate or no muscularis propria in the specimen. Bangladesh Journal of Urology, Vol. 18, No. 1, Jan 2015 p.16-22

scholarly journals Choice of the optimal treatment strategy for patient with multifocal bladder cancer: clinical case

2015 ◽  
Vol 11 (4) ◽  
pp. 102 ◽  
Author(s):  
I. A. Reva ◽  
A. V. Bormotin ◽  
E. A. Bormotin ◽  
M. V. Kovylina ◽  
A. N. Bernikov ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Strategy ◽  
Clinical Case ◽  
Optimal Treatment ◽  
Optimal Treatment Strategy

An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer

2010 ◽  
Vol 57 (1) ◽  
pp. 60-70 ◽  
Author(s):  
Girish S. Kulkarni ◽  
Oliver W. Hakenberg ◽  
Juergen E. Gschwend ◽  
George Thalmann ◽  
Wassim Kassouf ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Strategy ◽  
Critical Analysis ◽  
High Grade ◽  
Newly Diagnosed ◽  
T1g3 Bladder Cancer
Sign in / Sign up

Export Citation Format

Share Document